mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond

Mariona Estapé Senti, Lucía García Del Valle, Raymond M Schiffelers*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

27 Downloads (Pure)

Abstract

mRNA-based vaccines are emerging as a promising alternative to standard cancer treatments and the conventional vaccines. Moreover, the FDA-approval of three nucleic acid based therapeutics (Onpattro, BNT162b2 and mRNA-1273) has further increased the interest and trust on this type of therapeutics. In order to achieve a significant therapeutic efficacy, the mRNA needs from a drug delivery system. In the last years, several delivery platforms have been explored, being the lipid nanoparticles (LNPs) the most well characterized and studied. A better understanding on how mRNA-based therapeutics operate (both the mRNA itself and the drug delivery system) will help to further improve their efficacy and safety. In this review, we will provide an overview of what mRNA cancer vaccines are and their mode of action and we will highlight the advantages and challenges of the different delivery platforms that are under investigation.

Original languageEnglish
Article number115190
Pages (from-to)1-17
Number of pages17
JournalAdvanced Drug Delivery Reviews
Volume206
Early online date1 Feb 2024
DOIs
Publication statusPublished - Mar 2024

Keywords

  • Cancer
  • Immunotherapy
  • Ionizable lipid
  • Lipid nanoparticles
  • mRNA
  • Nucleic acid
  • Peptide-based nanoparticles
  • Polymeric nanoparticles
  • RNA modifications
  • type I interferon responses

Fingerprint

Dive into the research topics of 'mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond'. Together they form a unique fingerprint.

Cite this